Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
Natural killer T (NKT) cells constitute an important subset of T cells that can both directly and indirectly mediate antitumor immunity. However, we and others have reported that cancer patients have a reduction in both NKT cell number and function. NKT cells can be stimulated and expanded with α-GalCer and cytokines and these expanded NKT cells retain their phenotype, remain responsive to antigenic stimulation, and display cytotoxic function against tumor cell lines. These data strongly favor the use of ex vivo expanded NKT cells in adoptive immunotherapy. NKT cell based-immunotherapy has been limited by the use of autologous antigen-presenting cells, which can vary substantially in their quantity and quality. A standardized system that relies on artificial antigen-presenting cells (aAPCs) could produce the stimulating effects of dendritic cell (DC) without the pitfalls of allo- or xenogeneic cells. In this review, we discuss the progress that has been made using CD1d-based aAPC and how this acellular antigen presenting system can be used in the future to enhance our understanding of NKT cell biology and to develop NKT cell-specific adoptive immunotherapeutic strategies.
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Wenji
W
Sun
Priyanka B
PB
Subrahmanyam
James E
JE
East
Tonya J
TJ
Webb
D017951:Antigen Presentation; D000938:Antigen-Presenting Cells / Q000276:immunology*; D055610:Antigens, CD1d / Q000378:metabolism; D045744:Cell Line, Tumor / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D005699:Galactosylceramides / Q000378:metabolism; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D055611:Natural Killer T-Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D055610:Antigens, CD1d; D016207:Cytokines; D005699:Galactosylceramides; C493154:alpha-galactosylceramide